Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options YONGIN, South Korea, April 15, 2025 – 1ST ...

A single 60 mg dose of ARV-102 reduced LRRK2 protein by over 50% in cerebrospinal fluid and 90% in peripheral blood mononuclear cells. The Phase 1 trial showed ARV-102 was well tolerated ...

Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options YONGIN, South Korea, April 15, 2025 – 1ST ...